2010
DOI: 10.1159/000312654
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: Docetaxel and capecitabine are active agents in advanced gastric and gastroesophageal (GE) carcinomas. This multi-institutional phase II trial evaluates the combination of docetaxel and capecitabine as first- or second-line treatment in patients with advanced gastric and GE adenocarcinomas. Methods: Patients who had received 1 or no prior chemotherapy regimens were eligible. The chemotherapy regimen consisted of a 21-day cycle with docetaxel 30 mg/m2 administered on days 1 and 8 and capec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
10
0

Year Published

2010
2010
2017
2017

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(12 citation statements)
references
References 34 publications
2
10
0
Order By: Relevance
“…These results are comparable with earlier studies, reporting even higher rates of grade 3–4 neutropenia, in up to 23–80% of patients, febrile neutropenia among 2–12% and grade 3–4 non-neutropenic fever among 2–41% of patients, while hospitalization data are not readily available [19, 26, 27]. The incidence of mild palmo-plantar dysesthesia or hand-foot syndrome (HFS) was previously reported to be 9–42% and that of severe HFS 3–20% [19, 26, 27]. Even though the incidence of HFS in the current study was 45%, no grade 3–4 symptoms were detected.…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…These results are comparable with earlier studies, reporting even higher rates of grade 3–4 neutropenia, in up to 23–80% of patients, febrile neutropenia among 2–12% and grade 3–4 non-neutropenic fever among 2–41% of patients, while hospitalization data are not readily available [19, 26, 27]. The incidence of mild palmo-plantar dysesthesia or hand-foot syndrome (HFS) was previously reported to be 9–42% and that of severe HFS 3–20% [19, 26, 27]. Even though the incidence of HFS in the current study was 45%, no grade 3–4 symptoms were detected.…”
Section: Discussionsupporting
confidence: 90%
“…These findings are parallel to a previous trial of weekly docetaxel together with capecitabine on days 1–14 of a 21-day cycle, showing a comparable response rate of 29%, stable disease of 44% and overall survival reaching 10.7 months [26]. Another study investigating dose-dependent efficacy of docetaxel and capecitabine resulted in improved overall response rates with full dosing of these agents.…”
Section: Discussionsupporting
confidence: 81%
“…This toxicity profile is similar to weekly docetaxel plus capecitabine, which proved to be promising in gastric cancer, as shown by some phase 2 trials. 24,25 Although the incidence is not high, this toxicity may be troublesome for patients. Docetaxel-induced hand-and-foot syndrome is known to be related to the cumulative dose and occur more frequently in a weekly schedule.…”
Section: Discussionmentioning
confidence: 99%
“…Based on these findings, a regimen of further weekly D and OXA with a fluoropyrimidine is worthy of further exploration. Weekly D 30 mg/m 2 on days 1 and 8 in combination with an oral fluoropyrimidine (capecitabine) 825 mg/ m 2 twice a day on days 1-14 every 21 days demonstrated an overall response rate of 32%, and median survival was 10 months [23]. The major grade 3/4 adverse events were diarrhea in 5 patients (13%) and hand-foot syndrome in 5 patients (13%).…”
Section: Pneumonia (Death)mentioning
confidence: 99%